Imvexxy 2020 report

Imvexxy 2020 report
Imvexxy 2020 report
Posted in

[sf_modal header=”Sample Report Request” btn_colour=”lightgrey” btn_type=”standard” extraclass=”280-width” btn_size=”small” btn_text=” REQUEST A FREE SAMPLE”]

    Name (required)

    Company (required)

    Email Address (required)

    [/sf_modal]

    [sf_button colour=”lightgrey” link=/reports/ target=”_self” dropshadow=”no” extraclass=”set_t_width”]FIND ANOTHER REPORT[/sf_button]

    Imvexxy 2020 U.S. PROMOTIONAL AUDIT REPORT

    Published July 2021 • 21 Pages

    The 5 Key Questions Addressed by this Report:

    • How many physicians were reached by Imvexxy through reportable promotional activity in 2020 and how does this compare to its peer set in the Menopausal Syndrome market?
    • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
    • How does TherapeuticsMD’s depth of coverage vary within key specialties (e.g., Obstetrics/Gynecology, Family Medicine, and Urology) and how does this compare to its peers and the overall set of rep-accessible physicians?
    • How often are physicians receiving paid meals for Imvexxy throughout the year (e.g., monthly, quarterly, annually)?
    • Who were the most frequent meal recipients and top paid speakers for Imvexxy in 2020?

    Data Sources and Methodology:

    • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
    • Over 4,500 paid interactions across 3,300 physicians made on behalf of Imvexxy were carefully examined to support our analysis. In addition, interaction data from 4 peer products (e.g. Bijuva, Estring, Intrarosa, and Osphena ) was leveraged to provide benchmarking and market insights.